{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-065031","form_type":"8-K","ticker":"IRON","cik":"0001816736","company_name":"Disc Medicine, Inc.","filed_at":"2025-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.848698+00:00","generated_at":"2026-05-22T08:44:58.088491+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Disc Medicine Q1 net loss $34.1M, cash $694.7M; bitopertin NDA on track H2 2025","bullets":["Ended Q1 with $694.7M cash; expects to fund operations into 2028 after $259M January offering.","Net loss $34.1M vs $26.9M YoY; R&D expense $27.8M, SG&A $12.2M, both up on pipeline progress.","Bitopertin NDA in erythropoietic protoporphyria (EPP) planned for H2 2025; APOLLO confirmatory trial initiated.","DISC-3405 Phase 2 in polycythemia vera expected to start H1 2025; initial DISC-0974 data due H2 2025.","Successful CMC-focused end-of-Phase-2 meeting with FDA; drug substance and product manufactured in US."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-065031","json":"https://secwatch.observer/filing/0000950170-25-065031.json","markdown":"https://secwatch.observer/filing/0000950170-25-065031.md","text":"https://secwatch.observer/filing/0000950170-25-065031.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1816736/000095017025065031/0000950170-25-065031-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1816736/000095017025065031/iron-20250507.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T08:44:58.088491+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}